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Coordinated expression of viral genes in primary infection is essential for successful infection of host cells. We examined the expression
profiles of Kaposi’s sarcoma-associated herpesvirus (KSHV) transcripts in productive primary infection of primary human umbilical vein
endothelial cells by whole-genome reverse-transcription real-time quantitative PCR. The latent transcripts were expressed early and sustained at
high levels throughout the infection while the lytic transcripts were expressed in the order of immediate early, early, and lytic transcripts, all of
which culminated before the production of infectious virions. Significantly, transcripts encoding genes with host modulating functions, including
mitogenic and cell cycle-regulatory, immune-modulating, and anti-apoptotic genes, were expressed before those encoding viral structure and
replication genes, and sustained at high levels throughout the infection, suggesting KSHV manipulation of host environment to facilitate infection.
The KSHV transcriptional program in a primary infection defined in this study should provide a basis for further investigation of virus–cell
interactions.
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Kaposi’s sarcoma-associated herpesvirus (KSHV), also
known as human herpesvirus 8 (HHV8), is a gammaher-
pesvirus discovered in a Kaposi’s sarcoma (KS) lesion from
a patient with AIDS (Chang et al., 1994). KS is a highly
vascular angiogenic tumor consisting of proliferating spin-0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: gaos@uthscsa.edu (S.-J. Gao).dle-shape endothelial cells with an infiltration of inflamma-
tory cells (Roth et al., 1992). In the last two decades, KS
has evolved from a rare disease restricted to the Mediter-
ranean and Eastern European regions into an emerging
dominant malignancy in some African countries, and in
patients with AIDS in other parts of the world (Dedicoat
and Newton, 2003). Infection with KSHV is associated with
the development of all four clinical forms of Kaposi’s
sarcoma (KS), including epidemic AIDS-KS, endemic
African KS, immunosuppressive iatrogenic organ transplan-
tation KS, and classical KS. KSHV is also linked to the
development of primary effusion lymphoma (PEL) and a
subtype of multicentric Castleman’s disease (MCD) (Moore,
2000).05) 47 – 64
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S.M. Yoo et al. / Virology 343 (2005) 47–6448The KSHV genome consists of a 140.5-kb long-unique-
coding-region (LUR) and 30-kb terminal repeat (TR) sequence
(Russo et al., 1996). The LUR contains approximately 90
genes/Orfs, most of which encode for viral structural
proteins or proteins involved in viral replication. KSHV
also encodes a unique set of genes denoted by letter ‘‘K’’.
Molecular cloning studies have so far shown that over a
dozen KSHV genes have host/cellular regulatory functions,
including genes that are mitogenic and cell cycle-regulatory
(KIS, vIL-6, K-bZip, vIRF-1, Kaposin, vFLIP, vCyclin,
LANA, vGPCR, and LAMP), anti-apoptotic (vIL-6, vIAP,
vbcl-2, vIRF-1, vIRF-3, vIRF-2, and vFLIP), and immune-
modulating (KIS, vKCP, MIR1, vCCL-2, MIR2, vCCL-1,
Orf45, vIRF-1, vIRF-2, and vOx-2) (Dourmishev et al.,
2003; Russo et al., 1996). Further understanding of the
functions of KSHV genes in viral infection and replication,
and development of KSHV-related malignancies requires the
delineation of expression of KSHV genes during different
phases of viral infection.
KSHV genes are broadly classified as latent or lytic
genes, reflecting latent and lytic replication phases of the
virus, respectively. The lytic genes are further divided into
immediate early (IE), early, and late genes. The category to
which a gene belongs depends on its expression in the
infected host and KSHV-related malignancies, its response to
chemical inducers and inhibitors, and its homology to sister
genes of other herpesviruses. In KS lesions, the majority of
the tumor cells are latently infected by KSHV, which
indicates the importance of viral latent replication in the
development of KS (Moore and Chang, 2001). Nevertheless,
a small number of the infected cells also undergo sponta-
neous lytic replication. These lytic cycle cells are important
not only for sustaining the growth of KS tumors through
autocrine and paracrine effects by direct production of
KSHV-encoded cytokines or indirect induction of cellular
cytokines, but also for generating infectious virions that
spread to other cells. Thus, the delineation of the molecular
basis of KSHV latent vs. lytic replication, and that of
primary infection are essential for understanding the patho-
genesis of KSHV-induced malignancies. Although previous
studies have investigated the expression profiles of KSHV
genes in reactivation from latency in KSHV-infected PEL
cell lines by Northern-blot hybridization (Sarid et al., 1998;
Sun et al., 1999), microarray (Jenner et al., 2001; Paulose-
Murphy et al., 2001), or reverse-transcription real-time
quantitative PCR (RT-qPCR) (Fakhari and Dittmer, 2002),
definitions of the cellular and viral events in KSHV primary
infection have been hampered by the lack of an efficient and
sustainable infection system.
KSHV infects a variety of human cell types, including B,
T, endothelial, epithelial, fibroblast, and keratinocyte cells;
however, primary infection efficiencies in these systems are
usually low or cannot be sustained for long-term culture.
Furthermore, KSHV usually establishes a latent infection
immediately following infection of these systems (Krishnan et
al., 2004). The expression of KSHV genes in primary
infection was analyzed in default latent infection systems ofprimary human dermal microvascular endothelial cells
(HMVEC) and human foreskin fibroblast (HFF) in the first
8 and 24 h post-infection (h.p.i.), respectively, providing
some insights into the transcriptional program leading to
KSHV default latency (Krishnan et al., 2004). We have
recently established an efficient infection system by using a
recombinant KSHV BAC36 to infect primary human umbil-
ical vein endothelial cells (HUVEC) (Gao et al., 2003). In
contrast to other KSHV infection systems, KSHV infection of
HUVEC in this system is permissive at the early stage of
infection, producing large numbers of infectious virions.
Thus, unlike other KSHV infection systems, this system
resembles more closely the permissive infection systems of
other herpesviruses. In this system, KSHV primary infection
of HUVEC cultures reaches an infection efficiency of up to
90%, and consists of two phases. The first is a permissive
phase, in which the cultures undergo active viral lytic
replication, producing a large number of virions and
concomitantly resulting in large-scale cell death (Gao et al.,
2003). The second is a latent phase, in which cells surviving
the permissive phase switch into a latent infection, with a
small number of cells undergoing spontaneous viral lytic
replication, and proliferate into bundles of KS-like spindle
cells (Gao et al., 2003). In the current study, we used whole-
genome RT-qPCR to comprehensively assess the expression
profiles of KSHV transcripts in this productive primary
infection system by examining 10 time points (0–78 h.p.i.)
post-infection of HUVEC with BAC36. We found that
expression of KSHV genes occurred in a coordinated fashion
according to both gene class and gene function. Such highly
orchestrated events are likely essential to ensure a successful
KSHV primary infection and subsequent establishment of a
persistent infection in the host cells.
Results
Permissive primary infection of HUVEC by KSHV
We have previously shown that efficient primary infection
of HUVEC by KSHV is productive at the early stage of
infection (Gao et al., 2003). Since KSHV replication in this
system is different from those in other default latent infection
systems but more similar to the permissive infection systems
of other herpesviruses, we further examined the expression
profiles of KSHV genes in this distinct infection system.
HUVEC cultures were infected with high titers of BAC36
KSHV. Two days after infection, close to 90% of cells were
green fluorescent protein (GFP)-positive, an indication of
high efficient KSHV infection. As previously observed,
KSHV entered active lytic replication 4–5 day post-infection
(d.p.i.) as evidenced by the expression of a lytic protein mCP
encoded by Orf65 in close to 50% of infected cells and
active production of infectious virions (data not shown).
HUVEC infected by BAC36 at 10 different time points,
ranging from 0 (mock-infected control) to 78 h.p.i., were
collected for further analysis for KSHV transcriptional
program by RT-qPCR.
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A total of 92 primer pairs were used to examine the
expression profiles of KSHV transcripts (Table 1). The KSHV
genome has two gene clusters, Orf71/Orf72/Orf73 and Orf50/
OrfK8/OrfK8.1, that have multiple complex alternative splic-
ing transcripts. The positions of their primers are illustrated in
Fig. 1. To evaluate the relative sensitivity of each primer pair
for amplification of their target sequence, we used purified
BAC36 as a copy number control in qPCR. The results of
qPCR were determined by analyzing the melting curves and CT
values (Figs. 2A and B). Most of the primer pairs produced
melting curves with specific peaks using BAC36 DNA as
templates. The 24 primer pairs designed to amplify splicing
regions of the transcripts (Table 1) were not evaluated with
genomic DNA; however, these primer pairs also produced
melting curves with specific peaks when cDNA from KSHV-
infected samples was used as templates (Table 2). When the
primer pairs were used to amplify a fixed copy number of
KSHV genomes (1,091,642 copies), the average CT value was
24.5 T 4.5 (Fig. 2C). The Orf16 primer pair had the lowest CT
value (i.e., highest sensitivity, 18.2 T 1.1) while the Orf52
primer pair had the highest CT value (36.3 T 0.6). The
difference of CT value between Orf16 and Orf52 was 18.1
(CT
Orf16 – CT
Orf52 = 18.1), translating into 2.9  105 times
better amplification efficiency for Orf16 primers than Orf52
primers. The distribution range of CT values of the amplifiable
primer pairs was noticeably wide, reflecting variations in
amplification efficiency in qPCR (Fig. 2C). Under our
experimental conditions, the extrapolated sensitivities of the
primer pairs ranged from 1 (Orf16) to 2675 copies (Orf52)
(median, 1).
We then used the primer pairs in RT-qPCR to examine the
expression profiles of KSHV transcripts in primary infection of
HUVEC (Table 2). The mRNA samples were reverse-
transcribed into cDNA, which were then examined with all
the primer pairs in qPCR. None of the primer pairs detected
any amplification signal in the mock-infected cells. In contrast,
all the primer pairs detected the expression of their respective
transcripts in at least one time point of the KSHV-infected
HUVEC, except the Orf73(1) primer pair that detected only the
5.8 kb transcript (408 bp) instead of the intended 5.4 kb
transcript (74 bp) (Fig. 3D). The Orf73(1) primer set was
subsequently used for detecting the 5.8 kb transcript in this
study. These results demonstrated the specificity of the primers
for the detection of their respective transcripts in RT-qPCR.
Fig. 3A shows the melting curves of the Orf46 primer pair in
detecting its transcripts in KSHV-infected HUVEC at all 10
time points.
To determine the effect of amplification efficiency of a
primer pair in qPCR on the detection of its respective target
transcript(s), we plotted the CT value obtained from the
amplification of BAC36 DNA against the lowest CT value
(i.e., highest expression level) of all 10 time points of KSHV-
infected HUVEC after normalization to the CT value of
glyceraldehydes-3-phosphate dehydrogenase (GAPDH). Fig.
3C shows a strong linear correlation of amplification efficiencybetween episome DNA and transcripts from KSHV-infected
HUVEC (R2 = 0.5465, P value < 0.001), indicating that the
maximum amplification value of each transcript(s) is strongly
affected by the amplification efficiency of its primer pair.
Because of variation of different primer pairs in qPCR
amplification efficiency, and variation of different transcripts
in reverse-transcription (RT) efficiency, we decided not to
compare the absolute CT values between transcripts in the
subsequent analysis; rather, we analyzed the expression levels
of the same transcript at different time points by calibrating
them as percentages of the time point with maximum
expression value (Emax = 100%), i.e., %Emax. We first
normalized the CT value at a given time point to that of
GAPDH, and then to their respective Emax. The thick line in
Fig. 3B shows the expression kinetics of Orf46 calculated as
%Emax at different time points. We further examined all the
PCR products on gels to confirm that they had correct sizes,
and their relative intensities (expression) closely tracked those
calculated from CT values. To validate the results of RT-qPCR,
we examined several KSHV genes representing different
classes by semi-quantitative RT-PCR. Fig. 3D shows that the
relative intensities of all genes examined at different time
points closely tracked those calculated from their CT values
(Fig. 3D and Table 2). These results demonstrated the validity
of RT-qPCR in examining the expression of KSHV genes.
Expression kinetics of KSHV transcripts in primary infection of
HUVEC
All primer pairs detected the expression of their target
transcripts in more than one time point in KSHV primary
infection of HUVEC (Fig. 4). A number of transcripts had low
signals with relative maximum amplification values <0.0001
(Table 2). The expression kinetics of these transcripts, which
included Orf6, Orf9, Orf19, Orf34, Orf43, Orf45, Orf63,
Orf68, OrfK14/74(1), and OrfK14/74(2), were likely to be
less reliable. Of the 92 primer pairs, 19 (20.7%) detected
positive signals at 1 h.p.i., 25 (27.2%) at 3 h.p.i., 51 (55.4%) at
6 h.p.i., and 65 (70.7%) at 10 h.p.i. (Fig. 4). All 92 (100%)
primer pairs detected positive signals at 16 h.p.i. At 1 and 3
h.p.i., the overall KSHV gene expression level was very low
(median, 0 and 0.1%, respectively) (Fig. 4). While the 19
transcripts detected at 1 h.p.i. could be newly transcribed
transcripts, they could also be KSHV-encapsidated transcripts.
The expression of some KSHV transcripts, though remaining
low, was noticeable at 6 h.p.i. (median, 0.2%; range, 0 to
18.4%) (Fig. 4). Transcripts that had expression levels
>1%Emax at 6 h.p.i. included OrfK1, Orf4, Orf11, Orf16,
Orf33, Orf44, Orf57, Orf71, Orf71/72, Orf71-73, and Orf73(2)
(Table 2). The overall expression level started to increase at 16
h.p.i. and reached a peak at 54 h.p.i. (median, 100%; range,
23.9 to 100%) (Fig. 4); however, it decreased at 78 h.p.i.
(median, 62.7%; range, 0 to 100%). Since KSHV primary
infection of HUVEC is permissive at the early stage of
infection, we expected that the overall KSHV gene expression
peak level (54 h.p.i.) would precede the expression of lytic
proteins and virion production.
Table 1
KSHV primers used for reverse-transcription real-time quantitative PCR
Primer
pair
Gene location
(KSU75698)
Orientation
(splicing)a
Target position
(KSU75698)
Product
sizeb
Forward primer sequence Reverse primer sequence
OrfK1c 105–974 + 196–280 85 TGATTTCAACGCCTTACACG CGCAAAAGCCGAGTATTGTT
Orf4 1142–2794 + 2638–2702 65 GCCTCAGAGACCGCGAGA AGCGATTTTTAGACGCCGG
Orf6 3210–6611 + 5302–5367 66 CTGCCATAGGAGGGATGTTTG CCATGAGCATTGCTCTGGCT
Orf7 6628–8715 + 8259–8322 64 TTTATTTCCCAGTCCTCCAAATG GGGAAGCATGCCCGC
Orf8 8699–11236 + 11003–11065 63 CCCGACGTAGATCGCAGG GTTTTTGATTTCCTCCCGTGTT
Orf9 11363–14401 + 12070–12131 62 TAGGCGCTTCGTGCTGG CCGGATTGCTGCACTCGTA
Orf10 14519–15775 + 15583–15645 63 GGGCGTGGCAATGGC AAGCTGTATGGTGCCTGGCT
Orf11 15790–17013 + 16772–16833 62 CGGAATGGCGCCCAA GACGGGATGATCACTCGTGTT
OrfK2 17875–17261  17754–17690 65 ACCCTTGCAGATGCCGG GGATGCTATGGGTGATCGATG
Orf2 18553–17921  18119–18057 63 TGCTCGCCAGGCTTGG CGTGTTTCTCTCGCATGATAGC
OrfK3 19609–18608  (spl) 18809–18749 61 AGCCCCATCGCCCG TGAGCGGTATAGGGCCACTTAC
Orf70 21104–20091  20257–20197 61 AGGCGCGGAAAGGGAC AAACGCATATAGAGCCACTACGG
OrfK4 21832–21548  21795–21735 61 TTGTCCGGTCTATGCCAGG CTGCCTTGCTTTGTTTGCAA
OrfK5 26483–25713  (spl) 25987–25924 64 ACAAGGACCGTCAATTCGATG TGCCATACCGACGGCC
OrfK6 27424–27137  27393–27327 67 GGCGTGTACGACACGAGTGA GCGTACTGCTTGCCACGTT
OrfK7 28622–29002 + 28735–28793 59 GCCGCTTCTGGTTTTCATTG TTGCCAAAAGCGACGCA
Orf16 30145–30672 + 30344–30405 62 ACCAGCTTGGGTTGAGCATG GGCTCGCCCCCAGTTC
Orf17 32482–30821  30942–30879 64 GAGCGACTGCTGGCTTCAAC CGGTGGAGAAAGACGCTCC
Orf18 32424–33197 + 33113–33175 63 AACGTATGCGGTCTCGGGT GCACCAAGGTAGGCCAGCT
Orf19 34843–33194  33734–33673 62 ATACCAGGTTCAAGCGGCG TGGATTGCTGGAGTTTGGG
Orf20 35573–34611  35296–35233 64 CGGCTACTTAGAAACCGCCA CCACCTACCGCCGGC
Orf21 35383–37125 + 36960–37022 63 CGTAGCCGACGCGGATAA TGCCTGTAGATTTCGGTCCAC
Orf22 37113–39305 + 38129–38195 67 TCGGCAGTATGCGGAACTG AGTGGTGAACGTGGGCATG
Orf23 40516–39302  39467–39403 65 TGCCGTCACATATCAGTTCGA CCCCAAAGACCGTCAAAGC
Orf24 42778–40520  40890–40825 66 AGAAGTCAAACAGGCCCCG GTTCGTTTCTCAGGCTTGACG
Orf25 42777–46907 + 46509–46579 71 CTCGGCGACGTGCTATACAAT TGCCGACAAGGACTGTACATG
Orf26 46933–47850 + 47287–47519 233 AGCCGAAAGGATTCCACCAT TCCGTGTTGTCTACGTCCAG
Orf27 47873–48745 + 48313–48375 63 CACCACGTTTGGACGCATT TAATCCGTAGGCCTGCCGT
Orf28 48991–49299 + 49021–49083 63 GGAGGAATGGTGGACGGC AAGACCAATCACGGGAGGCT
Orf29bc 50417–49362  (spl) 50034–49917 118 GAAGTGCCTTGGAAAACAGC GCTTCTGGTGGGAGTCTGAG
Orf30 50623–50856 + 50707–50773 67 GAGCAAGTGGTCGCGGG TTTTGTGACATAGAGAGTCAGCGAG
Orf31c 50763–51437 + 51125–51217 93 TGTGCGGTATTTGCAGACAT ATAATGGCCGAGATGGTGTC
Orf32 51404–52768 + 52636–52698 63 GAGTCTTGTGGCATGCGTGA CCCCCAGGTAACACAAGCC
Orf33c 52761–53699 + 53492–53579 88 GACCGGGAATGGAGTGACTA AGCTGTTACCCTGCTCTGGA
Orf29ac 54676–53738  54302–54214 70 GGCCAGAAAAACACACGACT CGTTCAGAAAGGACGAAAGG
Orf34 54675–55658 + 55135–55196 62 ACCCCCTTCCGTTGCTATG ACAGTCGGCCCGACAAAA
Orf35 55639–56091 + 55838–55894 57 AGGCGGGCCAGAGGTTT GCGGCTGGCGCAAA
Orf36 55976–57310 + 57094–57153 60 CACCGGCAAAGCCCAG TGCTTCTGAAACGCCAGCT
Orf37 57273–58733 + 58593–58661 69 CCCGTCTACTTTCCCCGAG ACTTCTTGACCAAAAGTTGGCAG
Orf38 58688–58873 + 58743–58811 69 GGGAACCGCTCGACGTAGT GCTCAAGCAACATGCCCTTT
Orf39 60175–58976  59145–59083 63 TGGTCTTTGCTGGGAGGG CGCCGACGGTCGATAGAA
Orf40c 60308–61681 + 60665–60780 116 AACGTCAGAACACCCAGACC ATAGAGCTGTGCCACGTTCC
Orf41c 61827–62444 + 61986–62090 105 GGACCAGACACTGAGGGAAA GTTTAGGGCTCGTTCAATGC
Orf42 63272–62436  62837–62778 60 GACGAAGGCCGCGTCC ATTATTTGTCGCGCCAGAAAG
Orf43 64953–63136  63520–63454 67 GGATATGGTGTCCTGAGAATAGGTG GCTGGCTCCCGTTGTTGA
Orf44 64892–67258 + 66469–66533 65 GCCGGTGTCTCAAGAGCTG TGTCCCCCTCCTGCCC
Orf45 68576–67353  67668–67606 63 GCTTTGCGGCTTAAGTTTGG CGCCTCCTCTGGTAGCGA
Orf46c 69404–68637  68916–68813 104 CTGGGATTGGTTCACGAGTT TGAGCGGAGTTCTGTCAATG
Orf47 69915–69412  69486–69424 63 TTGACCTGCGTGCGCTC GGTTCTGTTAGCGGAAGTCAGAC
Orf48 71381–70173  (spl) 70495–70434 62 CGGGCAAGCAAGCTGGT CCCTGGCGATTTTGGGTAC
Orf49 72538–71630  72142–72081 62 ACAAAATGGGAGAGGCACCA GCGCCCCTGGAATCAGA
Orf50 71596–74629 + (spl) 71589–72645 98 (1057) CACAAAAATGGCGCAAGATGA TGGTAGAGTTGGGCCTTCAGTT
OrfK8(1) 74850–75569 + (spl) 75728–75795 68 CATGCTGATGCGAATGTGC AGCTTCAACATGGTGGGAGTG
OrfK8(2) 74850–75323 + (spl) 75800–76459 65 (660) TGTGCCGTCGTCCGG TGGATGGTTCCCCAGATGA
OrfK8/K8.1 76433–76714 + (spl) 76509–76583 75 TGGTGCTAGTAACCGTGTGCC TCTGCATTGTAGTGCGCGTC
OrfK8.1 75915–76695 + (spl) 76285–76539 160 (255) AAAGCGTCCAGGCCACCACAGA GGCAGAAAATGGCACACGGTTAC
Orf52 77197–76802  76915–76856 60 GGCACCAGGAGGCGGT TCGCTTAGAATCGACGTCTGC
Orf53 77665–77333  77543–77481 63 GCAACGTCATAGAATCCTGGG GCTCAGCGCCAGGCCT
Orf54 77667–78623 + 78444–78505 62 TTGCGCCATAGGAAGCTAGC TCGCGAAAATGCACTCGAG
Orf55 79448–78765  78889–78830 60 ACGAATGCATCGCGGAA CGGAGGCAACTTTACCCAAG
Orf56c 79436–81967 + 80735–80851 117 GACGGCCTAGAGCGATACTG CGATAGGCTGAGGTCATGGT
Orf57(1) 82081–83544 + (spl) 82091–82312 98 (222) TGGACATTATGAAGGGCATCCTA CGGGTTCGGACAATTGCT
Orf57(2) 82081–83544 + (spl) 82250–82312 63 ACGAATCGAGGGACGACG CGGGTTCGGACAATTGCT
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Table 1 (continued)
Primer
pair
Gene location
(KSU75698)
Orientation
(splicing)a
Target position
(KSU75698)
Product
sizeb
Forward primer sequence Reverse primer sequence
OrfK9 85209–83860  85347–85207 141 GGCCCACTAATATGTCAGCCA CATTGTCCCGCAACCAGACT
OrfK10 88164–86074  86577–86512 66 CCCAACAGGCCAGCTACATAA CTTCGTGGAACTCTGAGACGC
OrfK10.5(1) 91394–90936  (spl) 91020–90942 79 TGGTCTTCTCCGATGCTTCT TCACCTACACAGTGGGTCATCAC
OrfK10.5(2) 91394–90936  (spl) 90815–90753 63 TCCTCAGATTCCGCGCC TGAGGAGGATCACCCAGCC
OrfK10.5(3) 91394–90936  (spl) 90753–91020 177 (268) TCCTCAGATTCCGCGCC TCACCTACACAGTGGGTCATCAC
OrfK11 93367–91964  92092–92018 75 ATCCGAGTCATATTCAGGCGA AATCGAGAACCTGAAGGGTCC
Orf58c 95544–94471 + (spl) 95009–95121 113 TGCGGAGCATTTATGGTGTA TGCCTAAATGCCAAAAGTCC
Orf59c 96739–95549  95813–95715 99 CGAGTCTTCGCAAAAGGTTC AAGGGACCAACTGGTGTGAG
Orf60c 97787–96870  97246–97145 102 GCCTTGCCAACGATTACATT CGTGACTGGGTTTTTCCTGT
Orf61 100194–97816  97956–97891 66 CCCATCTTGTTTCATCCCAGA CTGACGGCTCTTCAGTGCC
Orf62 101194–100199  100283–100220 64 GCCACACGCGGCCTC TCTGAACGTGAAGGGCACG
Orf63 101208–103994 + 103279–103340 62 GCGACTTCGTGCGCGT ATGCGACAGATGTACGTGCG
Orf64 104000–111907 + 109840–109905 66 TGAGGTAATAAGGCAGCTGTGG GAAGCCGTGTCGGATTCATC
Orf65c 112443–111931  112340–112244 97 ATATGTCGCAGGCCGAATAC CCACCCATCCTCCTCAGATA
Orf66 113759–112470  112558–112494 65 GAACTCCAGCAGCTGTGAGGT CTGCCCTATTAAAGCACCGTG
Orf67 114508–113693  114437–114346 92 TCAGTCCCTGGATTTGGAAC CGTGCTGCATTCTAACCGTA
Orf68 114768–116405 + 115770–115833 64 GTGGTCGCATCCCACGA ATGGACCCTGTGAGGTGTCTG
Orf69 116669–117346 + 117241–117302 62 TGCAGTGCAGGTACACACCA GCATCTCGTCGGTGCAGTCT
OrfK12c 118101–117919  118070–117990 81 TTCATGTCCCGGATGTGTTA TAATCGCCAACAGACAAACG
Orf71c 122710–122291  122268–122156 113 GGATGCCCTAATGTCAATGC GGCGATAGTGTTGGGAGTGT
Orf72 123566–122793  (spl) 122996–122936 61 CATTGCCCGCCTCTATTATCA ATGACGTTGGCAGGAACCA
Orf71/72 123566–122793  (spl) 127875–123626 213 (4250) AGCTGCGCCACGAAGCAGTCA CAGGTTCTCCCATCGACGA
Orf71-73 127296–123808  (spl) 123688–123626 63 ACTGAACACACGGACAACGG CAGGTTCTCCCATCGACGA
Orf73(1) 127296–123808  (spl) 127837–127430 74 (408) GCTTGGTCCGGCTGACTTAT TGCAGTACCGCCCATGG
Orf73(2)c 127296–123808  (spl) 127563–127463 101 GCAGACACTGAAACGCTGAA AGGTGAGCCACCAGGACTTA
OrfK14/74(1) 127884–128930 + (spl) 128830–128890 61 TGGTGGGCCTATTTGGGATA GATGCACCG CCCTGCTT
OrfK14/74(2) 129391–130399 + (spl) 129198–129431 82 (234) TGGCCCAAACGGAGGATCCTAG AGTTTCATTCCAGGATTCATCATC
Orf75 134441–130551  131326–131257 70 GAGAACCCCGACAAGGACTG ACACGGGCTTTGAGGTGG
OrfK15c,d 136772–134762  (spl) 404–293 112 CCCAATGTATTCGGGTATGC TCCCACCATCAACCCTTAAA
GAPDHa GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC
a Glyceraldehydes-3-phosphate dehydrogenase primer pair was used as an internal control.
b The number in parenthesis represents calculated PCR product size based on KSHV genomic sequence (KSU75698).
c Primers were newly designed for this study. The rest of the primers were previously published (Fakhari and Dittmer, 2002). The primers were named after the
target gene(s).
d OrfK15 primer pair was designed according to the cDNA sequence (accession AY042973).
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KSHV-infected PEL cell lines serve as excellent systems
for examining the expression of KSHV genes in latent and
lytic replication cycles in B-cells. In uninduced cells, KSHV
is in the latent phase of replication, with a small number of
cells undergoing spontaneous lytic replication. Upon treat-
ment with chemical inducers such as 12-O-tetradecanoyl
phorbol-13-acetate (TPA), KSHV switches into lytic replica-
tion and produces infectious virions (Moore et al., 1996). We
compared the differential expression patterns of KSHV
transcripts in B-cells and endothelial cells by examining
uninduced BCBL-1 cells and BCBL-1 cells treated with TPA
for 2 days. All 92 primer pairs detected their target
transcripts in TPA-induced BCBL-1 cells, while 63 primer
pairs (68.5%) detected their target transcripts in uninduced
BCBL-1 cells (Table 2). In uninduced BCBL-1 cells, most
primer pairs detected low signals with only 15 of them
detecting signals higher than 10% of those in TPA-induced
BCBL-1 cells, of which 5 belong to latent transcripts
(OrfK12, Orf71, Orf72, Orf71/72, and ORF71-73). These
results confirm that uninduced BCBL-1 cells are generally in
the latent phase but the culture contains a small number ofcells undergoing spontaneous lytic replication (Sarid et al.,
1998).
The expression of KSHV transcripts in uninduced BCBL-1
cells was compared with that of TPA-induced BCBL-1 cells
after GAPDH calibration (Fig. 5A). Of the 92 primer pairs, 29
(30.5%) did not detect any signals in uninduced BCBL-1 cells
and therefore, the induction ratio of their transcripts could not
be calculated. These transcripts distributed at the baseline of
the x-axis of TPA-induced BCBL-1 cells. For the remaining
transcripts, 62 distributed above the 45- oblique line, indicating
their induction by TPA treatment (range, 1.3- to 16589.7-fold)
with only 1 transcript (OrfK4) distributed below the line,
indicating that it was not induced by TPA treatment (0.9-fold).
The median fold of increase after TPA-induction was 14.9 (Fig.
5B). Of note, the expression of 4 transcripts (Orf32, Orf44,
Orf68, and Orf69) was significantly increased after TPA
induction (>3000-fold), which was likely due to their low
expression levels in uninduced BCBL-1 cells (Table 2).
We compared the expression profiles of KSHV transcripts in
BCBL-1 cells with those in primary infection of HUVEC by
converting the relative expression levels to %Emax (Table 2).
The overall expression levels of KSHV transcripts in both
uninduced and TPA-induced BCBL-1 cells were lower than
Fig. 1. Transcripts and positions of primers for latent and lytic gene clusters. (A) Orf71/Orf72/Orf73 gene cluster transcribed three transcripts: two tricistronic
transcripts (5.8 kb and 5.4 kb) encoding all three genes, and one bicistronic transcript (1.7 kb) encoding Orf71 and Orf72. Orf71, Orf72, and Orf71-73 primer pairs
detected all three transcripts. The Orf71/72 primer pair only detected the 1.7 kb transcript. Both Orf73(1) and Orf73(2) primer pairs detected only the 5.8 transcript.
(B) Orf50/OrfK8/OrfK8.1 gene cluster transcribed multiple transcripts. The primer pairs did not distinguish all the transcripts.
S.M. Yoo et al. / Virology 343 (2005) 47–6452that of HUVEC at Emax. In uninduced BCBL-1 cells, the
expression median was 0.7%Emax (range, 0 to 73,058.9) and
only three transcripts had %Emax higher than 100% (Orf9 at
103.1%, OrfK4 at 133.3%, and OrfK7 at 73,058.9%). In TPA-
induced BCBL-1 cells, the expression median was 31.0%Emax
(range, 0 to 859,878.2) but 19 transcripts were expressed
higher than Emax, with 8 of them over 300%Emax (Orf9, OrfK2,
OrfK6, OrfK7, Orf19, OrfK8(1), Orf68, and OrfK14/74(2)).
The transcripts that had expression levels higher than Emax
were likely preferentially expressed in B-cells. In contrast, the
signals detected by 18 primer pairs were at least 3-fold lower
than the already low level of median expression of all KSHV
transcripts in TPA-induced BCBL-1 cells. Their respective
transcripts were likely preferentially expressed in endothelial
cells.
To determine the progression of KSHV replication in
primary infection of HUVEC, we clustered the expressionprofiles of KSHV transcripts with those of uninduced and TPA-
induced BCBL-1 cells (Fig. 6A). As expected, TPA-induced
BCBL-1 cells were clustered between the time points of 54 and
78 h.p.i., again confirming KSHV full lytic replication at these
time points. Interestingly, uninduced BCBL-1 cells were placed
between the time points of 10 and 16 h.p.i., indicating that
KSHV might be in a transient latent replication status during
this period.
Unsupervised clustering of expression profiles of KSHV
transcripts in primary infection of HUVEC
The expression profiles of KSHV transcripts in primary
infection of HUVEC comprised 5 clusters, each exhibiting a
distinct pattern (Fig. 6B). Fig. 7A illustrated the expression
median of each cluster. Cluster A consisted of 14 transcripts
that had maximal expression levels at 54 h.p.i. (median, 100%)
Fig. 2. Sensitivities of KSHV primers in real-time quantitative PCR. (A) Melting curve analyses with the MJR Opticon monitor program to determine the reading
temperature and amplified specific product (peak on melting curve). (B) Cycle threshold (CT) value was determined as the point at which the amplification plot
crossed the threshold line set automatically at 10 times the standard deviations of the baseline by the program. (C) CT values of the KSHV primers in amplifying a
fixed copy number of recombinant KSHV BAC36 (1,091,642 copies). The experiments were carried out twice, each with 3 repeats. The averages of CT values (solid
line) from both experiments (open and solid cycles) are plotted for each primer pair.
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Cluster B consisted of 25 transcripts that had maximal
expression levels at 54 h.p.i. (median, 100%) but declined
moderately to a median of 53.1%Emax at 78 h.p.i. Cluster C
consisted of 28 transcripts that had maximal expression levels
at 54 h.p.i. (median, 100%) but declined slightly to a median of
86.4%Emax at 78 h.p.i. Cluster D consisted of 9 transcripts with
a steady increase of expression levels up to 78 h.p.i. Cluster E
consisted of 16 transcripts with unique expression patterns that
were different from other clusters. The expression median of
cluster E transcripts was almost two times higher than that of
all the other transcripts at 24 h.p.i. (51.5% vs. 26.6%). Cluster
E also had maximal expression levels at 54 h.p.i. (median,
100%) and declined to a median of 56%Emax at 78 h.p.i.
Interestingly, the expression levels of cluster E transcripts were
generally low compared to other transcripts (Table 2). It is
worth noting that 27 of 29 transcripts with known functions inclusters A and B mainly encode for viral structural proteins or
proteins related to viral replication (Table 2). In contrast,
transcripts of genes that modulate immune functions or cell
growth and survival, including vKCP, LANA, vIRF-1, vCCL-
2, Orf45, LANA-2, KIS, vbcl-2, MIR2, Kaposin, MIR1,
vFLIP, vCyclin, vCCL-1, vIAP, vIL-6, LAMP, and vGPCR,
fell into clusters C, D, and E (Fig. 6B). These results suggest
that the expression of different KSHV functional gene groups
is modulated in a coordinated fashion in KSHV primary
infection.
Expression patterns of KSHV transcripts classified by gene
function
To further correlate expression patterns with gene functions,
we analyzed the expression profiles of different functional
groups of KSHV transcripts (Fig. 7B). Because some genes
Table 2
Expression profiles of KSHV genes in primary infection of HUVEC, and uninduced (U) and TPA-induced (I) BCBL-1 cells
Primer Gene/function F-classa Classb F.E.T. Clusterc HUVEC BCBL-1
0 1 3 6 10 16 24 36 54 78 MAX U I Fold
OrfK1 KIS F2/F4 6 C 4.8 6.3 5.0 48.2 51.2 87.7 100.0 0.0003 () 17.9 N.A.
Orf4 VKCP F2 6 C 13.9 2.1 5.7 21.9 44.7 100.0 68.3 0.0075 16.5 81.5 4.9
Orf6 SSB F1 Early 6 A 0.0 0.0 0.7 8.4 37.2 100.0 12.5 0.0000 () 15.3 N.A.
Orf7 Transport F1 Early 6 E 0.1 1.3 43.0 43.6 60.9 100.0 27.6 0.0032 () 32.5 N.A.
Orf8 GB F1 Late 10 B 0.0 10.4 23.6 50.9 100.0 41.1 0.0021 () 15.5 N.A.
Orf9 POL F1 Early 16 A 5.1 17.7 38.2 100.0 9.8 0.0000 103.1 1198.0 11.6
Orf10 F5 6 B 0.1 4.4 12.0 37.0 42.1 100.0 57.7 0.0323 32.2 195.9 6.1
Orf11 F5 6 B 18.4 11.8 25.5 25.3 41.7 100.0 79.2 0.6906 8.8 40.7 4.6
OrfK2 VIL-6 F2/F3/F4 Early 6 E 0.3 2.7 22.0 47.8 73.4 100.0 59.1 0.0021 28.5 2307.1 81.0
Orf2 DHFR F1 6 B 0.2 1.7 22.9 43.1 34.8 100.0 62.7 0.0091 0.7 10.6 15.9
OrfK3 MIR1 F2 6 D 0.2 2.2 43.6 44.5 48.8 81.7 100.0 0.1173 12.8 42.7 3.3
Orf70 TS F1 10 D 1.9 52.1 44.6 46.6 90.6 100.0 0.0346 1.9 26.6 13.7
OrfK4 vCCL-2 F2 Early 16 C 4.6 15.0 74.0 100.0 99.8 0.0001 133.3 120.2 0.9
OrfK5 MIR2 F2 Early 10 D 2.3 32.1 19.2 18.0 88.9 100.0 0.1476 7.4 82.1 11.2
OrfK6 vCCL-1 F2 Early 1 E 0.1 0.2 0.2 0.2 5.5 89.9 30.0 100.0 58.9 0.0006 33.3 3523.7 105.8
OrfK7 vIAP F3 1 E 0.0 0.0 0.0 0.0 1.2 93.1 83.9 100.0 83.7 0.0009 73,058.9 859,878.2 11.8
Orf16 vbcl-2 F3 Early 1 C 0.5 0.5 1.0 1.4 9.8 26.2 49.9 89.0 100.0 0.0681 8.4 42.3 5.0
Orf17 Assembly F1 Early 1 B 0.0 0.1 0.2 0.1 1.6 18.0 38.5 100.0 53.3 0.0123 1.0 74.6 77.4
Orf18 F5 16 C 7.6 26.6 43.3 100.0 66.7 0.0224 27.8 113.2 4.1
Orf19 Tegument F1 Early 16 A 1.0 10.1 28.4 100.0 13.5 0.0000 () 317.6 N.A.
Orf20 Fusion F1 Late 6 B 0.0 0.1 31.5 28.3 45.1 100.0 57.1 0.0005 () 1.5 N.A.
Orf21 TK F1 Early 10 B 0.0 9.7 26.9 33.9 100.0 49.7 0.0015 () 46.4 N.A.
Orf22 gH F1 Late 6 B 0.0 1.0 15.1 26.6 46.0 100.0 60.9 0.1527 2.1 28.5 13.5
Orf23 F5 1 C 0.0 0.2 0.8 2.0 9.6 23.1 37.7 95.3 100.0 0.0420 2.9 27.4 9.6
Orf24 F5 16 B 13.0 26.9 29.1 100.0 43.5 0.0024 () 0.0 N.A.
Orf25 MCP F1 Late 6 B 0.2 1.0 8.4 23.9 40.9 100.0 53.1 0.1714 0.3 10.3 33.4
Orf26 TRI-2 F1 Late 6 B 0.0 0.1 2.5 18.4 31.5 100.0 44.3 0.1051 () 11.9 N.A.
Orf27 F5 Late 6 B 0.0 0.3 2.7 19.0 39.2 100.0 47.1 0.0318 0.5 21.6 41.2
Orf28 F5 Late 16 C 3.8 41.9 50.4 100.0 81.9 0.0009 6.2 75.6 12.2
Orf29b Packaging F1 IE 10 E 0.7 13.5 58.7 83.7 100.0 30.7 0.0280 0.3 19.1 75.4
Orf30 F5 Late 6 E 0.1 1.7 6.6 50.9 63.3 100.0 42.5 0.0005 0.2 49.6 300.0
Orf31 F5 Early 6 E 0.3 2.2 5.9 53.3 74.0 100.0 25.6 0.0420 () 14.8 N.A.
Orf32 Tegument F1 Late 6 B 0.0 1.8 5.1 22.8 37.2 100.0 34.2 0.0030 0.0 18.5 16,589.7
Orf33 F5 Late 1 C 0.6 0.1 1.0 4.9 7.1 31.3 51.5 100.0 76.9 0.4509 0.2 2.4 13.5
Orf29a Packaging F1 Early 6 A 0.1 1.7 11.3 31.2 17.6 100.0 19.6 0.0035 0.0 17.5 375.9
Orf34 F5 16 A 3.4 18.9 22.3 100.0 18.1 0.0000 () 21.6 N.A.
Orf35 F5 10 A 5.4 13.6 28.2 23.3 100.0 11.6 0.0001 0.2 63.9 414.7
Orf36 Serine kinase F1 Early 10 B 11.4 19.2 47.3 46.8 100.0 50.9 0.0017 () 13.7 N.A.
Orf37 Exonuclease F1 Early 1 B 0.0 0.1 0.2 5.3 18.2 22.6 39.4 100.0 70.8 0.1441 3.1 27.1 8.8
Orf38 Tegument F1 1 D 0.0 0.0 0.1 6.6 24.6 15.7 31.7 63.8 100.0 0.1430 2.3 23.2 10.0
Orf39 gM F1 Late 3 A 0.0 0.0 0.0 0.6 11.8 17.9 100.0 21.7 0.0036 2.1 49.3 23.3
Orf40 PAF F1 Early 10 A 0.0 0.0 27.6 14.6 100.0 19.1 0.0014 0.4 79.1 216.4
Orf41 PAF F1 Early 6 B 0.3 1.9 7.5 40.0 30.8 100.0 62.5 0.0249 3.8 49.6 13.0
Orf42 F5 Late 10 A 0.3 2.6 8.2 14.8 100.0 18.5 0.0010 0.1 7.0 47.4
Orf43 F5 Late 16 A 0.0 1.0 25.4 100.0 6.3 0.0000 () 6.7 N.A.
Orf44 HEL F1 Early 6 B 4.7 7.7 11.1 15.0 56.9 100.0 38.6 0.0084 0.0 34.2 12,590.1
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Orf45 ORF45 F2 IE 16 C 0.1 15.4 59.9 100.0 58.9 0.0000 () 4.9 N.A.
Orf46 Uracil glucosidase F1 Early 1 B 0.1 0.1 0.2 0.5 5.5 29.3 27.3 100.0 42.3 0.4218 0.4 10.5 27.7
Orf47 gL F1 Late 10 B 0.2 16.4 34.2 40.2 100.0 85.9 0.0019 () 60.4 N.A.
Orf48 Glycoprotein F1 IE 16 C 6.7 20.0 44.6 100.0 83.0 0.0628 () 22.0 N.A.
Orf49 F5 Early 16 C 3.8 17.9 44.3 86.3 100.0 0.0577 0.4 45.1 121.1
Orf50 Rta F1/F4 IE 1 C 0.0 0.1 0.4 1.9 16.6 19.6 46.0 90.9 100.0 0.0052 2.5 79.5 31.3
OrfK8(1) K-bZip F1/F4 Early 6 C 0.2 1.1 12.9 34.9 56.6 100.0 66.6 0.0021 55.9 413.2 7.4
OrfK8(2) K-bZip F1/F4 Early 6 C 0.8 4.0 8.5 25.2 62.4 100.0 76.7 0.0080 6.9 125.7 18.2
OrfK8/K8.1 K-bZip F1/F4 Early 1 C 0.0 0.1 0.1 0.6 2.2 29.1 70.6 100.0 66.3 0.9540 1.8 23.9 13.1
OrfK8.1 Glycoprotein F1 Late 1 C 0.2 0.1 0.1 0.1 1.9 42.1 89.6 88.3 100.0 4.0028 1.4 20.8 14.9
Orf52 F5 Late 16 A 0.0 2.9 8.5 100.0 4.6 0.0003 0.0 2.8 513.8
Orf53 F5 Late 16 C 0.4 8.1 37.2 100.0 72.2 0.0008 () 3.8 N.A.
Orf54 dUTPase F1 Early 16 B 18.5 11.9 38.0 100.0 58.9 0.0005 () 6.2 N.A.
Orf55 F5 Late 3 D 0.1 0.3 0.2 2.8 4.9 6.8 79.0 100.0 0.0107 2.3 33.5 14.6
Orf56 PRI F1 Early 16 C 6.4 58.2 49.9 96.3 100.0 0.0199 () 6.7 N.A.
Orf57(1) Mta F1 Early 6 E 0.9 19.7 62.9 85.2 94.4 100.0 74.3 0.0066 2.8 196.2 71.3
Orf57(2) Mta F1 Early 6 D 1.7 16.7 40.3 31.7 52.3 91.5 100.0 0.0736 2.8 81.3 28.8
OrfK9 vIRF-1 F2/F3/F4 Early 1 C 0.1 0.1 0.4 0.6 4.7 16.0 42.3 100.0 86.8 0.0369 7.4 109.9 14.8
OrfK10 F5 1 C 0.0 0.0 0.1 0.3 2.6 10.0 52.8 100.0 73.5 0.0538 2.7 29.5 10.9
OrfK10.5(1) vIRF-3 F3 Latent 10 C 0.4 4.3 59.5 72.3 87.4 100.0 0.0002 () 9.9 N.A.
OrfK10.5(2) vIRF-3 F3 Latent 16 C 2.6 8.6 46.5 91.0 100.0 0.0046 () 53.1 N.A.
OrfK10.5(3) vIRF-3 F3 Latent 16 C 4.0 12.2 88.8 100.0 58.5 0.0240 1.6 72.0 43.7
OrfK11 vIRF-2 F2/F3 10 B 0.2 2.2 6.3 17.8 100.0 50.1 0.0009 2.3 55.6 24.3
Orf58 F5 Late 3 E 0.0 0.0 0.2 11.4 38.3 52.9 100.0 47.5 0.1225 0.7 11.7 15.7
Orf59 PPF F1 Early 10 B 0.4 20.0 40.0 42.0 100.0 59.6 1.3775 1.9 27.1 14.6
Orf60 Small RNR F1 Early 3 B 0.0 0.0 1.0 29.0 33.9 50.4 100.0 81.6 0.2649 0.2 13.1 57.1
Orf61 Large RNR F1 Early 10 A 0.1 8.6 17.7 24.9 100.0 25.5 0.0067 () 7.2 N.A.
Orf62 TRI-1 F1 Late 16 E 11.3 42.0 52.5 100.0 53.1 0.0064 () 21.8 N.A.
Orf63 Tegument F1 Early 16 B 4.2 15.3 29.9 100.0 27.9 0.0000 0.8 172.9 229.3
Orf64 Tegument F1 Early 16 A 2.3 6.8 31.4 100.0 15.7 0.0001 () 168.4 N.A.
Orf65 SCIP F1 1 C 0.0 0.0 0.0 0.1 2.0 23.5 59.4 75.6 100.0 0.7887 0.2 1.7 10.2
Orf66 F5 Early 1 C 0.0 0.1 0.0 0.1 4.0 17.8 35.3 75.7 100.0 0.1483 5.1 49.5 9.6
Orf67 Tegument F1 Early 1 C 0.0 0.0 0.0 0.1 6.9 29.6 45.3 74.3 100.0 0.2118 1.1 37.1 35.0
Orf68 Glycoprotein F1 Early 16 C 2.3 20.3 75.0 100.0 86.1 0.0000 0.1 501.8 3497.2
Orf69 F5 Early 16 B 2.1 16.2 29.1 100.0 25.6 0.0014 0.0 47.5 5579.8
OrfK12 Kaposin F4 Latent 1 D 0.0 0.0 0.8 0.6 4.8 15.1 31.9 56.9 100.0 1.7894 9.9 52.4 5.3
Orf71 vFLIP F2/F3 Latent 3 E 0.2 1.3 7.4 42.3 73.3 100.0 83.0 80.0 0.0647 5.9 7.7 1.3
Orf72 vCyclin F4 Latent 6 E 0.0 2.0 31.4 80.5 84.7 100.0 65.0 0.0239 4.7 16.8 3.6
Orf71/72 1.7 kb transcript F2/F3/F4 Latent 3 D 0.2 12.7 14.8 36.7 67.5 69.6 77.6 100.0 0.0009 37.3 109.8 2.9
Orf71-73 vFLIP, vCyclin, LANA F2/F3/F4 Latent 1 D 0.0 0.2 1.7 2.7 28.1 40.7 45.5 67.7 100.0 0.2892 1.4 8.1 5.8
Orf73(1) LANA F2/F3/F4 Latent 16 E 16.6 37.5 87.7 100.0 68.6 0.0009 () 177.3 N.A.
Orf73(2) LANA F2/F3/F4 Latent 6 C 1.7 2.9 13.5 18.0 53.4 100.0 81.0 0.0158 6.6 131.1 19.7
OrfK14/74(1) vOx-2, vGPCR F2 16 A 1.5 61.0 7.7 100.0 0.0 0.0000 () 3.3 N.A.
OrfK14/74(2) VOx-2, vGPCR F4 Early 16 E 0.1 43.9 100.0 23.9 50.7 0.0000 () 1341.5 N.A.
Orf75 FGARAT F1 16 E 1.2 38.3 100.0 69.1 71.8 0.0017 () 0.0 N.A.
OrfK15 LAMP F4 Early 16 E 4.5 52.0 57.6 100.0 44.6 0.0186 () 1.5 N.A.
F.E.T.: first expressed time point.
MAX: relative maximum amplification value. U: uninduced BCBL-1 cells. I: BCBL-1 cells induced with TPA for 48 h. N.A.: not applicable.
a Functional class: F1, structure and replication; F2, immune-modulating; F3, anti-apoptosis; F4, mitogenic and cell cycle-regulatory; F5, unknown.
b Gene class defined by other investigators.
c Cluster defined by unsupervised clustering analysis.
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Fig. 3. Quantification and validation of KSHV transcripts in primary infection of HUVEC. (A) Representative analysis of melting curves of Orf46 primers in
detecting its specific transcripts in KSHV primary infection of HUVEC. The melting curves of Orf46 and GAPDH primers are shown in solid and dotted lines,
respectively. GAPDH primers detected strong peak in all the samples. The specific peak detected by Orf46 primers started to appear at as early as 1 h.p.i. and
continued to increase at the later time points. (B) Calculation of the relative expression levels of Orf46 transcripts during KSHV primary infection of HUVEC by
analysis of CT values (thick line) and quantification of PCR products on gels from Fig. 2D (thin line). CT values or band intensities at different time points were
normalized to their respective GAPDH values and then converted to percentages of expression (%Emax), relative to the maximum expression value (Emax). %Emax
values from all time points were used to plot the expression kinetic curve (see calculation method details in Materials and methods). (C) Scatter plot of CT values
from the amplification of BAC36 episomes (x-axis) vs. the lowest CT values (highest expression levels) of all time points in the KSHV primary infection of HUVEC
( y-axis). Each point represents a primer pair. (D) Validation of PCR products of representative KSHV genes on gels. The size of a specific PCR product is indicated
on the right side of its corresponding gel. Note that the sizes of some PCR products are very close to those of their primer dimers. The intensities of the primer dimers
decreased when those of specific amplified products increased.
S.M. Yoo et al. / Virology 343 (2005) 47–6456had more than one function, their transcripts were classified
into more than one group. In general, transcripts encoding
proteins with immune-modulating functions (F2, n = 14), anti-
apoptotic functions (F3, n = 13), and mitogenic or cell cycle-
regulatory functions (F4, n = 15) were expressed before those
encoding structural proteins and proteins related to viral
replication (F1, n = 44). Transcripts with unknown functions
or that did not belong to any of the above groups were
classified as group F5 (n = 22). The expression order of
different functional groups at 50%Emax was F3 (29.5 h), F4
(30.5), F2 (36 h), F1 (38.8 h), and F5 (39.2 h). These resultswere in general consistent with those obtained by unsupervised
clustering analysis.
Expression patterns of KSHV transcripts classified by gene
class
To analyze the expression patterns of different classes of
KSHV transcripts, we further grouped the expression profiles
of KSHV transcripts by gene class based on previous
classification of KSHV genes (Sarid et al., 1998; Sun et al.,
1999). Although individual genes in each class manifested
Fig. 4. Number of KSHV transcripts and overall median expression levels
detected by KSHV primer pairs at different time points during KSHV primary
infection of HUVEC.
S.M. Yoo et al. / Virology 343 (2005) 47–64 57fluctuated expression patterns, the patterns of median expres-
sion levels of lytic transcripts (IE, early, and late) were similar
while the latent class showed a distinct pattern (Fig. 7C). The
latent class was expressed first and had already reached
15%Emax by 16 h.p.i. and 71%Emax by 36 h.p.i. In contrast,
the lytic classes only reached 6.4%Emax at 16 h.p.i. and
44.3%Emax at 36 h.p.i. The latent class also had the feature of
cluster D, with a steady increase of expression levels up to 78
h.p.i. (median, 100%Emax). Among the lytic transcripts, the
IE class was expressed slightly earlier, followed by early and
late classes. The calculated time points for latent, IE, early,
and late classes to reach 10%Emax were 13.5, 16, 17.5, and
18.5 h.p.i., respectively, and 50%Emax were 26, 35, 38.5, and
39 h.p.i., respectively. These data indicated that, during
KSHV primary infection, the latent class transcripts were
expressed first and followed by IE, early, and late class
transcripts. The expression of the latent class transcripts was
also sustained throughout the infection, and was consistently
higher than those of other classes at all the time points except
at 54 h.p.i. (Fig. 7C).
Expression patterns of KSHV transcripts classified by
expression peak time
The expression peak time points of KSHV transcripts could
also reflect the status of viral replication (Fig. 7D). Only three
transcripts, Orf71, OrfK14/74(2), and Orf75, reached their
expression peak at 36 h.p.i. (P36) (Table 2). After 36 h.p.i., the
expression levels of these transcripts started to moderately
decline until 78 h.p.i. (median, 62.6%). The majority of the
transcripts (67, 72.8%) peaked expression at 54 h.p.i. (P54).
Almost all transcripts encoding viral structural proteins and
proteins related to viral replication belonged to the P54 group.
Since this group represented the majority of the transcripts, its
expression kinetics closely mimicked that of the overall
expression pattern of KSHV transcripts. The last group
consisted of 22 transcripts that peaked in expression at 78
h.p.i. (P78). The P78 group consisted of most latent transcripts,
including OrfK12, Orf71-73, Orf71/72, OrfK10.5(1), andOrfK10.5(2), several immune-modulating transcripts (Orf16,
OrfK3, and OrfK5), and a viral replication transactivator
Orf50. The P78 group had most of the transcripts in clusters
C and D. Because we were not able to calculate the actual
expression peak time of the P78 group transcripts, their %Emax
at different time points might not reflect the actual proportion
of expression levels.
Expression kinetics of KSHV splicing transcripts
We analyzed the expression profiles of gene clusters
Orf71/Orf72/Orf73 and Orf50/OrfK8/OrfK8.1, which encode
genes that are important for KSHV latent or lytic
replication, respectively. The Orf71/Orf72/Orf73 cluster
transcribed three transcripts: two tricistronic transcripts (5.8
kb and 5.4 kb) encoding all three genes, and one bicistronic
transcript (1.7 kb) encoding Orf71 and Orf72 (Fig. 1A).
Orf71 and Orf72 primer pairs were located within their
respective coding frames, and both detected all three
transcripts. The Orf71-73 primer pair was adjacent to the
Orf72 coding frame and also detected all three transcripts.
The Orf71/72 primer pair was designed specifically for the
1.7 kb transcript and located on two exons between a large
splicing region. Theoretically, it should amplify a product of
213 bp from the 1.7 kb transcript, and products of 4250 bp
and 3916 bp from the 5.8 and 5.4 kb transcripts,
respectively. Because of preferential amplification of the
smaller product, this primer pair only detected the 213 bp
product from the 1.7 kb transcript (Fig. 3D). The Orf73(1)
primer pair was adjacent to the Orf73 coding frame and
between the small splicing region of the 5.4 kb transcript. In
theory, it should detect a 74 bp product from the 5.4 kb
transcript and a 408 bp product from the unspliced 5.8
transcript; however, gel analysis of its PCR product revealed
that it detected only the 408 bp product from the 5.8
transcript in both HUVEC (Fig. 3D) and BCBL-1 cells (data
not shown). The Orf73(2) primer pair was also adjacent to
the Orf73 coding frame and could only detect the 5.8 kb
transcript.
For primer pairs that detect the same transcript(s), their
overall expression patterns were similar (Orf71 vs. Orf72 vs.
Orf71-73, and Orf73(1) vs. Orf73(2) in Table 2 and Fig. 6B);
however, the expression of an individual transcript or
combinations of transcripts detected by these primer pairs
displayed different patterns, suggesting that these transcripts
were differentially expressed during KSHV infection of
HUVEC. Differential expression of the Orf71/Orf72/Orf73
gene cluster was also observed in BCBL-1 cells (Table 2).
We also found differential expression patterns of the
Orf50/OrfK8/OrfK8.1 gene cluster (Fig. 6B). Although
transcripts of this gene cluster used the same 3V-poly(A)
signals, they were expressed as different classes of genes:
Orf50 as an IE gene, K8 as an early gene, and K8.1 as a late
gene (Seaman et al., 1999; Sun et al., 1999). Our primer pairs
were not able to distinguish all the known transcripts.
Nevertheless, differential expression of the transcripts of this
gene cluster in both BCBL-1 cells and HUVEC was evident
Fig. 5. Expression of KSHV transcripts in uninduced and TPA-induced BCBL-1 cells detected by reverse-transcription real-time quantitative PCR. (A) Scatter plot of
CT values of uninduced ( y-axis) vs. TPA-induced (x-axis) BCBL-1 cells. All CT values were the averages of two independent experiments, each with 3 repeats. All
data were normalized to the CT values of GAPDH; therefore, GAPDH CT values were placed at the position (0,0). Each circle represents the transcript detected by its
primer pair. Latent transcripts are labeled with solid circles. The oblique line was placed at the position where transcripts were expressed equally in uninduced and
TPA-induced BCBL-1 cells. If a transcript was positioned on the line, its expression was not altered by TPA induction. If a transcript was positioned above or below
the line, its expression was up- or down-regulated by TPA induction, respectively. Transcripts without detectable signals in uninduced BCBL-1 cells were positioned
at the baseline of the X-axis of TPA-induced BCBL-1 cells. Note that the CT values had a negative correlation with the actual expression values. (B) Fold-induction
of KSHV transcripts by TPA in BCBL-1 cells. Latent transcripts are represented as open bars.
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h.p.i. and reached 10%Emax at 13 h.p.i. Both Orf50 and
OrfK8.1 were classified into group P78 while K8(1), K8(2),
and K8/K8.1 were classified into group P54. As indicatedpreviously, transcripts in group P78 could not be compared
directly to other groups. However, since the peak expression
level of Orf50 was beyond 78 h.p.i., the actual %Emax of
Orf50 could be higher than the estimated values.
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We have examined the expression profiles of KSHV
transcripts in a productive primary infection of HUVEC by
whole-genome RT-qPCR. The overall expression patterns of
KSHV transcripts reflected the status of virus infection and
replication. The expression median of KSHV lytic transcripts
lagged behind that of latent transcripts at the early time points
of infection and followed the order of IE, early, and late
transcripts (Fig. 7C), which was consistent with the previous
classification of KSHV genes (Sarid et al., 1998; Sun et al.,
1999). KSHV lytic transcripts increased steadily and peaked at
54 h.p.i. The progression rate of the KSHV lytic transcriptional
program is comparable to those of some other herpesviruses
(Cohrs et al., 2003; Goodrum et al., 2002; Martinez-Guzman et
al., 2003). The maximum expression of lytic proteins and
production of virions occur at 4 d.p.i. in this primary infection
model (Gao et al., 2003). Thus, maximum expression of KSHV
lytic transcripts preceded the production of infectious virions.
Clustering analysis placed the expression pattern of KSHV
transcripts in TPA-induced BCBL-1 cells between the time
points of 54 and 78 h.p.i. (Fig. 6A), confirming the active lytic
transcriptional activity of KSHV at these time points.
Although KSHV usually remains latent in immunocompe-
tent infected subjects, it can be reactivated in certain clinical
conditions such as immunosuppression following an HIV
infection, or iatrogenic organ transplantation. If primary
infection in vivo is productive, it would trigger an avalanche
of KSHV lytic replication through continuous production of
large amounts of infectious virions and spreading to uninfected
cells for new productive infection. This process would also
directly produce virus-encoded cytokines and signaling mole-
cules, such as vIL-6 and vGPCR, and indirectly induce cellular
inflammatory cytokines, and therefore contribute to the
aggressive progression of KS in these clinical conditions.
While the overall expression level of KSHV IE transcripts
preceded those of other lytic transcripts, only one of them,
Orf50, which encodes a master transactivator of KSHV lytic
replication, was expressed at the early time points. The
expression of the Orf50 transcript was detected as early as 1
h.p.i., but remained low until 16 h.p.i. The other 3 IE
transcripts (Orf29b, Orf45, and Orf48) were not expressed
until 16 h.p.i. (Table 2). Early expression of Orf50 could leadFig. 6. Hierarchal clustering of expression profiles of KSHV transcripts in
HUVEC and BCBL-1 cells. The relative expression level %Emax was used for
clustering analyses of data obtained from primary infection of HUVEC.
Similarly, for BCBL-1 cells, the sample with the higher expression level was set
as 100%, from which the expression level of the other sample was calculated
accordingly. (A) Transcripts from uninduced (U) BCBL-1 cells were clustered
between 10 and 16 h.p.i. while transcripts from TPA-induced (I) BCBL-1 cells
were clustered between 54 and 78 h.p.i. (B) Hierarchal clustering of expression
profiles of KSHV transcripts in primary infection of HUVEC. The names of
transcripts are labeled in color according to gene class (latent in green, IE in
red, early in violet, late in blue, and unclassified in black). Gene functional
groups are also labeled in color (structure and replication in red, immune-
modulating in brown, anti-apoptosis in yellow, mitogenic or cell cycle-
regulatory in green, and unknown group in gray).
Fig. 7. Classification of expression profiles of KSHV transcripts by non-supervised clustering (A), gene function (B), gene class (C), and expression peak time (D).
Cluster analysis was performed with the Cluster 3.0 software (Eisen et al., 1998) after adjusting the expression values by normalization and median centering. Gene
functions were defined based on previous studies (Dourmishev et al., 2003). Transcripts encoding genes with more than one function were classified into more than
one group. Gene classes were defined based on previous studies (Sarid et al., 1998; Sun et al., 1999). Expression peak time was defined as the time when the
transcript reached maximum expression value Emax.
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transcripts, most of which did not increase until 24 h.p.i.
(Table 2). Interestingly, while the expression of almost all lytic
transcripts started to decline after 54 h.p.i., the expression of
the Orf50 transcript continued to increase. Sustained expres-
sion of Orf50 might be necessary for the completion of a
productive lytic replication, since it has a direct role in DNA
replication by acting as a transacting factor of KSHV lytic
origin of DNA replication (AuCoin et al., 2004). On the other
hand, we also observed induction of latent transcripts by TPA
(Table 2), an effect that was most likely due to Orf50 induction
of Orf73 promoter (Lan et al., 2005). It can be envisaged that,
besides its role in activating KSHV lytic replication, Orf50
might also have a function in KSHV latency, i.e., by promoting
the expression of KSHV latent genes and establishment of
latency after the shutdown of the lytic transcriptional program
during primary infection.
The overall expression levels of KSHV lytic transcripts
remained low before 36 h.p.i. (median <50%); however, latent
transcripts were sustained at a relatively high level from the
early time points and reached 78.4% Emax at 36 h.p.i. (Fig. 7C).
It was likely that KSHV established a transient latent infection
early in infection, a prediction which was consistent with the
results of clustering analysis that placed uninduced BCBL-1
cells between the time points of 10 and 16 h.p.i. (Fig. 6A).
Nevertheless, even if such transient latency did exist, it was
quickly disrupted by the initiation of viral lytic replication and
expression of lytic genes. The overall expression level of
KSHV lytic transcripts declined after 54 h.p.i., but those of
latent transcripts continued to increase (Fig. 7C). These results
were consistent with our previous observation that the majorityof KSHV-infected cells in the culture likely entered into latent
replication after the initial phase of lytic replication (Gao et al.,
2003). The continuous expression of high levels of KSHV
latent transcripts, particularly those in the Orf71/72/73 gene
cluster, could be important in virus switch from lytic to latent
replication.
When analyzed by gene function, we found that KSHV
transcripts encoding genes with host/cell regulatory functions,
such as those with mitogenic and cell cycle-regulatory, anti-
apoptotic, and immune-modulating functions, were generally
expressed earlier and maintained at higher levels both before
and after the 54 h.p.i. lytic peak time point than transcripts
encoding genes of viral structure and replication proteins (Fig.
7B). These genes, including vKCP, LANA, vIRF-1, vCCL-2,
Orf45, LANA-2, KIS, vbcl-2, MIR2, Kaposin, MIR1, vFLIP,
vCyclin, vCCL-1, vIAP, vIL-6, LAMP, and vGPCR, are likely
important in KSHV manipulation of the cellular environment
and countering innate immunity induced during primary
infection, to facilitate virus entry and productive replication,
and establishment of persistent infection in the host cells.
We detected weak expression of 19 transcripts as early as 1
h.p.i. The possibility of association of viral episomes or
genomic contaminants with purified virions can be excluded
because the total RNA prepared from KSHV-infected HUVEC
was treated with RNase-free DNase before RT reaction, and
qPCR for genomic DNAwith these primer pairs failed to detect
any signal before the RT reactions. It was also unlikely that
viral transcripts were non-specifically associated with the
surface of the purified virions, because it would not be possible
for them to survive the virion purification and infection
procedures. Therefore, these transcripts were either de novo
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demonstrated that CMV transcripts can be packaged into
virions and delivered into infected cells (Bresnahan and Shenk,
2000; Prichard et al., 1998). Regardless of the pathways to
reach early expression, the early presence of these transcripts
might play a critical role for the successful infection of host
cells. A number of genes encoded by these transcripts indeed
have host modulating functions, including vCCL-1, vIAP, vbcl-
2, vIRF-1, Kaposin, vFLIP, vCyclin, and LANA.
A previous study examined the expression profiles of KSHV
genes in primary infection in non-productive default latent
infection systems of HMVEC and HFF at 8 and 24 h.p.i.
(Krishnan et al., 2004). Comparison of KSHV expression
profiles in this system with those of our productive system
should help to understand the transcriptional programs and
strategies for manipulating cellular pathways employed by
KSHV in these contrast default latent and productive infection
systems. Both studies observed early expression of latent and
host-modulating genes, as well as the key IE gene, RTA. In
contrast to our observation that both latent and host modulating
genes were sustained beyond 78 h.p.i., the expression of host
modulating genes and all the other lytic genes, including RTA,
declined sharply by 24 h.p.i. in the default latent systems.
Furthermore, only 31% of the KSHV genes were detected in the
default latent systems, reflecting non-productive lytic replication
(Krishnan et al., 2004), while all the KSHV genes were detected
in our current study. Thus, the observed KSHV transcriptional
programs in both studies appeared to authentically mirror the
actual KSHV replication programs in primary infection. It is
particularly interesting that both studies observed early expres-
sion of host modulating genes in primary infection, suggesting
the importance of manipulating the host pathways in KSHV
primary infection.
It is unclear why KSHV productive infection was observed in
our system but not in others. As we have previously discussed
(Gao et al., 2003), the presence of defective viruses in viral
preparations could account for this difference. In fact, we have
observed a high prevalence of KSHV defective viruses in PEL
cell lines from which viral preparations were generated in other
studies (Deng et al., 2004). In our studies, we prepared infectious
virions from a full-length recombinant KSHV to reduce the
problem (Zhou et al., 2002). It remains possible that the use of
different cell types and experimental infection procedures could
influence and determine whether a KSHV primary infection is
productive.
We identified candidate endothelial or B-cell specific
transcripts. The transcripts that were preferentially expressed
in B-cells could have important roles in KSHV infection and
induction of malignancies of B-cell origins. In contrast,
transcripts that were preferentially expressed in endothelial
cells could have important functions in the development of
KS. For transcripts that have extremely high expression levels
in B-cells, OrfK2, OrfK6, and OrfK7 are of particular interest.
These transcripts encode proteins that regulate cell growth
and survival. OrfK2 encodes an IL-6 homolog (vIL-6), which
is a B-cell growth and differentiation factor linked to plasma
cell abnormalities, as well as myeloid and lymphoidmalignancies. Previous studies have shown that the expres-
sion levels of vIL-6 are high in both PEL and MCD but less
consistent in KS tumors (Cannon et al., 1999; Parravicini et
al., 1997; Staskus et al., 1999). It remains to be determined
whether OrfK6 encoding a chemokine homolog vCCL-1 and
OrfK7 encoding an inhibitor of apoptosis protein homolog
vIAP also have strong expression in PEL and MCD. The
expression profile of OrfK4 transcript, which encodes another
chemokine homolog vCCL-2, is also of interest. While
previous studies showed that OrfK4 was an inducible
transcript (Sarid et al., 1998), our results indicated that it
was poorly induced by TPA treatment, and thus could
represent another previously unidentified latent transcript. It
is possible that vCCL-2 has a predominant function during
KSHV latent infection while vCCL-1 has more important role
during KSHV lytic replication.
It has been shown that OrfK10.5 encoding a homolog of
interferon regulatory factor (IRF), vIRF3/LANA2, is expressed
in PEL but not in KS tumor (Rivas et al., 2001). In
concordance with previous studies, OrfK10.5 was expressed
in BCBL-1 cells; however, our results showed that OrfK10.5
was also expressed in endothelial cells during KSHV primary
infection. Another IRF homolog, vIRF1, a KSHV oncogene
encoded by OrfK9 transcript has been characterized as an early
gene but recently shown to be expressed in KS tumors
(Dittmer, 2003; Gao et al., 1997; Wang et al., 2001). Our
results indicated that it was also expressed in HUVEC during
KSHV primary infection. These results suggest that both IRF1
and IRF3 could have important roles during KSHV primary
infection.
We observed differential expression of alternatively spliced
transcripts of a number of genes/gene clusters (Fig. 6B).
Among them, the Orf71/72/73 gene cluster is of particular
interest because of the expression patterns of its transcripts,
and the functions of its encoded genes in latency and in the
regulation of the cell cycle and survival of latently-infected
cells. The expression of transcripts encoded by this gene
cluster is controlled by the same cis-regulatory region,
LANAp, which has characteristics resembling an IE gene
promoter. Consistent with this promoter feature, we observed
induction of all three latent polycistronic transcripts by TPA
in BCBL-1 cells (Table 2). Although TPA could have an
unexpected effect on the house-keeping gene GAPDH that
could lead to suboptimal calibration of their expression levels,
a number of other studies have reported similar levels of
induction of these latent transcripts after treatment with TPA
or butyrate in PEL cell lines (Paulose-Murphy et al., 2001;
Sun et al., 1999). It would be interesting to determine how
the differential expression of these transcripts is controlled
and whether such patterns could also lead to differential
expression of their encoded proteins.
Although unsupervised clustering analyses of expression
profiles of KSHV transcripts classified them into 5 clusters,
they can be grouped into 2 major groups that reflect not only
their expression patterns, but also their gene class and gene
function. The first major group consists of clusters A and B, in
which most transcripts are lytic transcripts encoding viral
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second major group consists of clusters C, D, and E that
include most transcripts encoding genes with cell-modulating
and latency-associated functions. Thus, the expression of
KSHV genes is regulated at a coordinated fashion. Such
highly orchestrated events are likely essential for ensuring
successful viral infection and the establishment of persistent
infection in the host cells.
Materials and methods
Cell lines, primary cells, and cell culture
BCBL-1 and 293 cells harboring a recombinant KSHV
BAC36 (BCBL-1BAC36 and 293BAC36, respectively) were
described previously (Zhou et al., 2002). BCBL-1BAC36 cells
were cultured in RPMI-1640 medium supplemented with 10%
fetal bovine serum (FBS, Sigma, St. Louis, MO), 50 Ag/ml
gentamicin, 150 Ag/ml hygromycin, and 2 mM glutamine.
293BAC36 cells were cultured in Dulbecco’s modified eagle’s
medium (DMEM) supplemented with 10% FBS, 50 Ag/ml
gentamicin, 150 Ag/ml hygromycin, and 2 mM glutamine.
Primary HUVEC cultures were obtained from Clonetics
(BioWhittaker, Inc., Walkersville, MD) and cultured in
Endothelial Cell Growth Medium Bullet Kit, containing hEGF,
hFGF-B, VEGF, ascorbic acid, hydrocortisone, long R3-IGF-1,
and heparin, as instructed by the manufacturer (Clonetics).
Induction of KSHV lytic replication and preparation of
infectious virus
To induce KSHV lytic replication, cells were treated with 20
ng/ml of TPA (Sigma) for 5 days as previously described (Zhou
et al., 2002). To prepare a high titer of infectious virus
preparation, supernatant from the TPA-induced culture was
centrifuged at 5000  g for 30 min to eliminate cell debris,
filtered through a 0.45-Am-pore-size filter, and centrifuged
again at 100,000  g for 1 h using a 20% sucrose cushion. The
final pellet was resuspended in culture medium overnight, and
adjusted to one tenth of the original volume to give a
concentration factor of 10X. Undissolved debris was eliminat-
ed by centrifugation at 5000  g for 10 min. All the procedures
for virus concentration were handled at 4 -C. Fresh virus
preparations with titers of about 2  106 GFP cells/ml were
used for infection experiments.
Virus infection
HUVEC at 70 to 80% confluency seeded in 75 cm2 flasks
1 day before were infected with KSHV (Gao et al., 2003).
Briefly, flasks of 75-cm2 containing approximately 3  106
cells/flask were infected with 3 ml/flask of a virus
preparation with a titer of 2  106 GFP cells/ml. The
infection efficiency was determined by monitoring GFP
expression at 2 d.p.i. and estimated to be ¨90% for this
study. Duplicate infected HUVEC cultures were harvested at
10 separate time points (0, 1, 3, 6, 10, 16, 24, 36, 54, or 78h.p.i.). The cells from duplicate flasks were combined for
subsequent analyses.
RT-qPCR
Total RNA from KSHV- or mock-infected HUVEC was
prepared with TRI reagent as recommended by the manufac-
turer (Sigma, St. Louis, MO). The RNAwas resuspended in 50
Al of diethyl pyrocarbonate-treated water, quantified, and
treated with RQ1 RNase-free DNase according to the instruc-
tions of the manufacturer (Promega, Madison, WI). RNA (5
Ag) was reverse-transcribed in a total volume of 40 Al to
obtain the first-strand cDNA using the Superscript III first-
strand synthesis system (Invitrogen, Carlsbad, CA). A control
without reverse transcriptase was conducted in parallel. qPCR
was then performed with the cDNA. The primers for KSHV
transcripts and GAPDH are listed in Table 1. Seventy-five
KSHV primer pairs were previously described (Fakhari and
Dittmer, 2002) while another 17 primer pairs were newly
designed for this study. qPCR was carried out in a total
volume of 20 Al, including 10 Al of DyNAmo SYBR Green
qPCR kit (MJ Research, Reno, NV), 0.5 Al of each primer at
50 AM, and 1 Al of cDNA at 15 ng/Al. To determine the
sensitivity of the primer pairs, we used purified recombinant
KSHV BAC36 episome DNA as a copy number control
(Zhou et al., 2002). We used 1 Al of BAC36 DNA at 0.2 ng/
Al in each reaction, corresponding to 1,091,642 episomes/
reaction. Thermal amplification was performed in a DNA
Engine Opticon 2 continuous fluorescence detector (MJ
Research), using the following linked profile: 10 min at 96
-C, and then 45 amplification cycles, each with denaturation
(95 -C for 10 s), annealing (60 -C for 20 s), and extension
(72 -C for 15 s) periods. After amplification, melting curve
analysis was carried out by increasing the annealing
temperature by 0.2 -C per step from 65.0 -C to 95.0 -C.
Fluorescence intensity was detected at 5 temperatures (72, 74,
76, 78, and 80 -C) after the extension step, and calculated by
Opticon MONITOR analysis software (MJ Research) (Fig.
2A). The cycle threshold (CT) value was determined as the
point (cycle) at which the amplification plot crossed the
threshold line (Fig. 2B). The threshold line was automatically
set at 10 times of the standard deviation of the baseline by the
program. For some primer pairs, the primers can form dimers
and could potentially be misread as real products. Therefore,
for each primer pair, we chose a temperature that fell between
the peaks of the specific amplified product and primer–dimer
by analyzing the melting curve to determine the CT value
(Fig. 2A).
Data analysis
All samples were examined by RT-qPCR in triplicate for
each primer pair, together with controls of parallel samples
without RT reaction, controls of samples without template, and
internal controls of GAPDH amplification in each experiment.
Two experiments were independently carried out. All CT
values were normalized to the CT values of GAPDH obtained
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of GAPDH). The differential value (DDCT) between the
normalized DCT values of two time points was then averaged
for the experiments and converted to the actual fold of
difference (2DDCT). For the analysis of relative expression
levels of the same transcript at different time points and in
BCBL-1 cells, the data were converted to percentages relative to
the value of the time point with maximum expression level in
KSHV primary infection of HUVEC (%Emax). The definition
and formula of calculation for each parameter are shown below:
CT, threshold of cycle
DCT, CT value of an experiment sample calibrated by CT of
internal standard GAPDH:
DCT ¼ CTSample  CTGAPDH
DDCT, differential CT value between the normalized DCT
values of two time points
Esample, actual expression value of an experimental sample:
ESample ¼ 2DCTSample
Emax, the highest expression value within a series of
samples amplified by the same primer pair:
Emax ¼ max ESample1; ESample2; ESample3; N
 
%Emax, the percent of an expression value of a sample in
relative to the Emax in a given time kinetics series:
%Emax ¼ ESample
Emax
 100
ClusteringFor cluster analysis, the expression profiles of KSHV
transcripts were clustered with Cluster 3.0 software (Eisen et
al., 1998). The expression values were adjusted by normaliza-
tion and median centering. Hierarchical clustering was per-
formed by complete linkage clustering with uncentered
correlation option.
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